Disease Overview：Membranous Nephropathy（MN）
Membranous nephropathy (MN) is an autoimmune glomerular disease characterized by subepithelial immune complex deposition, leading to thickening of the glomerular basement membrane and podocyte injury. It is a common cause of nephrotic syndrome in adults, presenting with heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Primary MN is mediated by autoantibodies—most frequently anti-PLA2R or anti-THSD7A—while secondary forms may arise from infections, malignancies, or autoimmune conditions such as lupus. Diagnosis relies on renal biopsy with immunofluorescence and electron microscopy, supplemented by serum autoantibody testing. Management is risk-stratified: low-risk patients often undergo conservative monitoring, while moderate-to-high-risk cases require immunosuppression—typically rituximab or calcineurin inhibitors—to preserve renal function and reduce progression to end-stage kidney disease.
China offers distinct advantages for MN treatment: its top-tier nephrology centers—many affiliated with universities like Peking Union Medical College Hospital and Shanghai Renji Hospital—combine deep expertise in glomerular disease with access to advanced diagnostics, including PLA2R/THSD7A serology, digital pathology, and real-time therapeutic drug monitoring. Clinical outcomes align with international benchmarks: published cohort studies report 60–75% complete or partial remission rates at 12–24 months with rituximab-based regimens. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising quality—generic biologics, streamlined protocols, and integrated multidisciplinary care contribute to this value. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying physician credentials, arranging appointments at accredited hospitals, providing itemized, transparent pricing in advance, coordinating translation, accommodation, and post-discharge follow-up—all tailored to individual clinical and logistical needs.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Membranous Nephropathy (Nephrology Department)
Non-Surgical / Conservative / Medication-Based Therapy
*Indicated for low-risk patients (spontaneous remission likely), moderate proteinuria (<8 g/day), stable eGFR (>60 mL/min/1.73m²), no anti-PLA2R antibodies or low titer.*
- •Observation + ACEi/ARB monotherapy
- *Costs (USD):* - Baseline labs (urine ACR, serum creatinine, albumin, anti-PLA2R IgG, complement C3/C4): $45 - Monthly urine ACR + serum creatinine: $12/session × 6 months = $72 - Lisinopril or telmisartan (6-month supply, generic): $18 - Total (6 months): $135
- •Immunosuppression (Rituximab-based regimen)
- *Costs (USD):* - Pre-treatment workup (HBV/HCV/HIV serology, chest X-ray, ECG, CBC, LFTs): $68 - Rituximab (375 mg/m² IV × 2 doses, 2-week interval): $1,420 (includes infusion nursing, monitoring) - Post-infusion CD19+ B-cell count (at 3 months): $32 - Total (first year): $1,520
- •Cyclophosphamide + Corticosteroid (Ponticelli regimen)
- *Costs (USD):* - Pre-treatment labs + bone marrow aspiration (if age >65): $95 - IV cyclophosphamide (0.5 g/m² × 6 monthly doses) + oral prednisone taper: $310 - Monthly CBC, LFTs, urinalysis: $24/month × 6 = $144 - Total (6 months): $549
Surgical / Procedural / Interventional Options
*No surgical intervention is indicated for membranous nephropathy itself. Kidney biopsy is diagnostic—not therapeutic—and performed only once at diagnosis.*
- •Percutaneous Renal Biopsy (Ultrasound-guided)
- *Pre-biopsy workup (INR, platelets, renal US):* $38 - *Biopsy procedure (incl. pathology: light/electron microscopy + immunofluorescence):* $295 - *Total:* $333
Special / Complex Condition Management
- •Refractory disease (no response after 6–12 months rituximab)
- *Plasma exchange (5 sessions, 1.5× plasma volume):* $1,850 (includes albumin replacement, anticoagulation, monitoring)
Quick Selection Guide
- •Young adult (<50), anti-PLA2R+, high proteinuria: Rituximab ($1,520) — optimal efficacy/safety balance.
- •Elderly (>70), comorbid diabetes/hypertension, mild proteinuria: ACEi/ARB observation ($135) — avoids immunosuppression risks.
- •Budget-constrained patient (<$500), moderate severity: Cyclophosphamide regimen ($549) — lower upfront cost than rituximab; requires close hematologic monitoring.
- •Rapidly declining eGFR + hypoalbuminemia (<2.5 g/dL): Immediate biopsy ($333) + rituximab — confirms diagnosis and guides urgent therapy.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Membranous Nephropathy Medical Vacation Packages
Curated transparent all-inclusive packages combining Membranous Nephropathy treatment with China top medical destinations:
